Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registry.
Chimenti MS, Fatica M, Fornaro M, Lopalco G, Corrado A, Rotondo C, Semeraro A, Colella S, Praino E, Gorla R, Bazzani C, Babaglioni G, Foti R, Floris A, Frediani B, Atzeni F, Conti F, Cauli A, Caporali R, Iannone F, Guiducci S. Chimenti MS, et al. Among authors: gorla r. Clin Exp Rheumatol. 2024 Nov;42(11):2221-2228. doi: 10.55563/clinexprheumatol/udiit0. Epub 2024 Jul 24. Clin Exp Rheumatol. 2024. PMID: 39051160 Free article.
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry.
Sebastiani M, Venerito V, Bugatti S, Bazzani C, Biggioggero M, Petricca L, Foti R, Bortoluzzi A, Balduzzi S, Visalli E, Frediani B, Manfredi A, Gremese E, Favalli E, Iannone F, Ferraccioli G, Lapadula G; Contributors. Sebastiani M, et al. Clin Rheumatol. 2021 Oct;40(10):4039-4047. doi: 10.1007/s10067-021-05734-3. Epub 2021 Apr 21. Clin Rheumatol. 2021. PMID: 33881676
Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs.
Scagnellato L, Collesei A, Doria A, Cozzi G, Lorenzin M, Atzeni F, Bugatti S, Caporali R, Cauli A, Conti F, Corrado A, Carletto A, Chimenti MS, Foti R, Frediani B, Gerli R, Gorla R, Govoni M, Gremese E, Guiducci S, Iagnocco A, Iannone F, Parisi S, Rossini M, Salaffi F, Santo L, Sarzi Puttini P, Sebastiani M, Semerano A, Ferraccioli G, Lapadula G, Ramonda R; GISEA Study Group. Scagnellato L, et al. Among authors: gorla r. Clin Exp Rheumatol. 2024 Jan;42(1):104-114. doi: 10.55563/clinexprheumatol/q38lu0. Epub 2023 Aug 30. Clin Exp Rheumatol. 2024. PMID: 37650298
Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicentre study.
Bazzani C, Scrivo R, Andreoli L, Baldissera E, Biggioggero M, Canti V, Gerosa M, Pontikaki I, Ramoni V, Trespidi L, Zatti S, Caporali R, Gorla R, Iannone F, Lojacono A, Meroni P, Montecucco C, Motta M, Sabbadini MG, Valesini G, Tincani A. Bazzani C, et al. Among authors: gorla r. Clin Exp Rheumatol. 2015 Sep-Oct;33(5):688-93. Epub 2015 Aug 25. Clin Exp Rheumatol. 2015. PMID: 26311348
Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.
Monti S, Klersy C, Gorla R, Sarzi-Puttini P, Atzeni F, Pellerito R, Fusaro E, Paolazzi G, Rocchetta PA, Favalli EG, Marchesoni A, Caporali R. Monti S, et al. Among authors: gorla r. Clin Rheumatol. 2017 Apr;36(4):753-761. doi: 10.1007/s10067-016-3528-y. Epub 2017 Jan 5. Clin Rheumatol. 2017. PMID: 28058538 Free article.
Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.
Iannone F, Ferraccioli G, Sinigaglia L, Favalli EG, Sarzi-Puttini P, Atzeni F, Gorla R, Bazzani C, Govoni M, Farina I, Gremese E, Carletto A, Giollo A, Galeazzi M, Foti R, Bianchino L, La Grasta L, Lapadula G. Iannone F, et al. Among authors: gorla r. Clin Rheumatol. 2018 Feb;37(2):315-321. doi: 10.1007/s10067-017-3846-8. Epub 2017 Oct 5. Clin Rheumatol. 2018. PMID: 28980085
Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA.
Atzeni F, Sarzi-Puttini P, Sebastiani M, Panetta V, Salaffi F, Iannone F, Carletto A, Foti R, Gremese E, Govoni M, Marchesoni A, Favalli E, Gorla R, Ramonda R, Ferraccioli G, Lapadula G; GISEA group.. Atzeni F, et al. Among authors: gorla r. Clin Exp Rheumatol. 2019 Jul-Aug;37(4):649-655. Epub 2019 Feb 11. Clin Exp Rheumatol. 2019. PMID: 30767865
Impact of one-year treatment with biotechnological drugs on work ability in patients with rheumatoid arthritis in Italy: a prospective real-life study.
Manara M, Caporali R, Lomater C, Gorla R, Fusaro E, Sarzi-Puttini P, Stobbione P, Capri S, Sinigaglia L. Manara M, et al. Among authors: gorla r. Clin Exp Rheumatol. 2021 Mar-Apr;39(2):263-268. doi: 10.55563/clinexprheumatol/q69z52. Epub 2020 Jun 19. Clin Exp Rheumatol. 2021. PMID: 32573407 Free article.
141 results